The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | CAR T-cell therapy and transplantation for hematological malignancies
Arnon Nagler, MD, from Chaim Sheba Medical Center, Tel-Aviv, Israel, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA). Prof. Nagler reports that despite the promising results of CAR T-cell therapy, the therapy is still in a premature stage for replacing transplant treatments and stresses the need to resolve the limitations of CAR T-cell therapy before it can become a routine intervention.
